We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Healthcare Alliance Offers Real-Time PCR Test for HIV

By Biotechdaily staff writers
Posted on 25 Oct 2007
A healthcare alliance has offered a real-time polymerase chain reaction (PCR) test for human immunodeficiency virus (HIV) to its members.

The new HIV-monitoring test, the Cobas TaqMan 48 Analyzer and Cobas TaqMan analyzer, is a fully automated, closed-tube system that makes molecular testing practical for everyday lab use. More...
This real-time PCR analyzer is compact and robust, provides a broad linear range, and integrates easily into the lab.

Premier (San Diego, CA, USA) added the new Roche (Basel, Switzerland) HIV-1 monitoring test, Cobas TaqMan 48 analyzer and Cobas TaqMan analyzer, to an existing three-year molecular contract so that customers could combine the Cobas Ampliprep, which was included in the existing molecular contract, with the Cobas TaqMan and the docking station to experience full automation.

Premier Inc., a large U.S. healthcare alliance, gave its 1,700 hospital members access to the Roche Cobas Ampliprep/Cobas TaqMan® HIV-1 assay--the only real-time PCR test for HIV offered to its members.

"Adding the Roche HIV-1 monitoring test to Premier's menu is consistent with our mission to quickly roll out the highest level of innovation to our customers,” said John Biggers, group vice president of sourcing at Premier. "Premier also added Cobas TaqMan 48 Analyzer, Cobas TaqMan analyzer and Roche's unique docking station so that customers could take advantage of the test's full automation while offering to their patients the most advanced HIV-1 monitoring assay based on 11 years of experience in HIV monitoring.”

Roche introduced the fully automated Cobas Ampliprep/Cobas TaqMan in response to customers' needs for a system that could allow their molecular laboratory technicians to load samples and walk away, not returning until the sample results are ready.

"Molecular technicians are in high demand,” said Susan Zienowicz, vice president for molecular diagnostics of Roche Diagnostics. "In creating the Cobas Ampliprep/Cobas TaqMan HIV-1 assay, we provide labs with another strategy to help them leverage their employees' time and get more done in the lab.”

Owned by not-for profit hospitals, Premier operates a large healthcare purchasing network, and a comprehensive repository of hospital clinical and financial information.


Related Links:
Premier
Roche

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.